A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-27. Anything still debated is marked as such rather than presented as settled.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
=== Central & East Indo-Pacific === 2024 Vietnamese export of pangasius maw has increased to about US$58,000,000, with 38% going to China and the rest to Thailand, Malaysia, Singapore and the USA. The Vietnam News Agency claims that the falling totoaba population has incentivized Chinese import of alternative maw. The island and seas of New Guinea see significant fish maw production. Since 2012, in and around the Kikori River delta of Papua New Guinea, the scaly croaker Nibea squamosa has been targeted in gillnetting for its extremely high-priced maw, selling for as much as US$15,615 per kilogram.
== Further reading == Bernard, MA; Valli, VE (1977). "Familial renal disease in Samoyed dogs". The Canadian Veterinary Journal. 18 (7): 181–9. PMC 1697612. PMID 884645. Meyers, VN; Jezyk, PF; Aguirre, GD; Patterson, DF (1983). "Short-limbed dwarfism and ocular defects in the Samoyed dog". Journal of the American Veterinary Medical Association. 183 (9): 975–9. doi:10.2460/javma.1983.183.09.975. PMID 12002589. S2CID 32585084. Kimmel, SE; Ward, CR; Henthorn, PS; Hess, RS (2002). "Familial insulin-dependent diabetes mellitus in Samoyed dogs". Journal of the American Animal Hospital Association. 38 (3): 235–8. doi:10.5326/0380235. PMID 12022409.
== Structure == Reticular fiber is composed of one or more types of very thin and delicately woven strands of type III collagen. These strands build a highly ordered cellular network and provide a supporting network. Many of these types of collagen have been combined with carbohydrate. Thus, they react with silver stains (argyrophilic) and with periodic acid-Schiff reagent but are not demonstrated with ordinary histological stains such as those using hematoxylin. The 1953 Science article mentioned above concluded that the reticular and regular collagenous materials contains the same four sugars – galactose, glucose, mannose, and fucose – but in a much greater concentration in the reticular than in the collagenous material. In a 1993 paper, the reticular fibers of the capillary sheath and splenic cord were studied and compared in the pig spleen by transmission electron microscopy. This paper attempted to reveal their components and the presence of sialic acid in the amorphous ground substance. Collagen fibrils, elastic fibers, microfibrils, nerve fibers, and smooth muscle cells were observed in the reticular fibers of the splenic cord. On the other hand, only microfibrils were recognized in the reticular fibers of the capillary sheath. The binding of LFA lectin to the splenic cord was stronger than the capillary sheath. These findings suggested that the reticular fibers of the splenic cord include multiple functional elements and might perform an important role during contraction or dilation of the spleen.
The two got official approval from Valve to release Sven Co-op on Steam as a standalone title in 2012, though opted to wait nearly a year to announce this in July 2013 to give their team time to develop a hotfix for the current version of the mod. This standalone title was released on January 22, 2016, and includes all the assets for Half-Life required to play that game without installing the original game; players are still required to have purchased and installed Opposing Force and Blue Shift to play those in the standalone release of Sven Co-op. The standalone version includes updated versions of the Half-Life campaign maps, improved versions of popular maps developed for Sven Co-op, and additional scripting tools that will allow level designers to further customize new maps beyond the default GoldSrc. McDermott stated that their team anticipates continuing to improve tools for level designers, such as being able to replace the game's default heads-up display, though as the game is still developed in the team's free time, there is no information on when these will be available.
Sources: en.wikipedia.org
In 2024, Israel also placed sanctions on the Houthis. In September 2026, the G7 foreign ministers issued a joint statement condemning Houthi attacks on Saudi Arabia and calling on Iran to end its support for the Houthis.
=== Altered platelet function === Congenital Disorders of adhesion Bernard–Soulier syndrome Disorders of activation Disorders of granule amount or release Hermansky–Pudlak syndrome Gray platelet syndrome ADP receptor defect Decreased cyclooxygenase activity Platelet storage pool deficiency Disorders of aggregation Glanzmann's thrombasthenia Wiskott–Aldrich syndrome Disorders of coagulant activity COAT platelet defect Scott syndrome Acquired Disorders of adhesion Paroxysmal nocturnal hemoglobinuria Asthma Aspirin-exacerbated respiratory disease (AERD/Samter's triad) Cancer Malaria Decreased cyclooxygenase activity
Not all techniques by themselves will mitigate all hazards. Although flocculation followed by filtration has been suggested as best practice this is rarely practicable without the ability to carefully control pH and settling conditions. Ill-advised use of alum as a flocculant can lead to unacceptable levels of aluminium in the water so treated. If water is to be stored, halogens offer extended protection.
== Research and publications == Kalra has emphasised the importance of person-centred care for over a decade through his reviews, research, and communications in various national and international journals. One of his earlier citations on this topic dates back to a paper he led in 2013, in which he described the role of a person-centred approach during insulin initiation and intensification—one of the most challenging aspects of diabetes management.79 Although a substantial body of his work has focused on diabetes,77,79 he has also applied the principles of person-centred care to other chronic metabolic disorders, including obesity, hypogonadism, and hypothyroidism.78 Kalra has written on menopause distress and late-onset male hypogonadism, simplifying their definitions and describing person-centric thresholds, targets, tools, and techniques for management.167,168 He is also the lead author of a paper titled Thyroid Tantrums in Teenagers, which highlights the variability in endocrine presentations during adolescence and addresses management, assessment, testing techniques, associated biomedical illness, and training. His work extends across all age groups; for instance, he has published geriatric goalposts on independence and interdependence, emphasising the importance of person-centric care in older adults. Key principles of person-centred care highlighted in Kalra's publications include effective communication with patients.65,102 Other core principles include ensuring that therapy is affordable and that the management plan is feasible for the patient.
== Size exclusion chromatography == Prior to these studies, HPLC analyses were tuned by modifying the mobile and stationary phases only. Gradient elution for HPLC merely meant changing the ratio of solvents to improve column efficiency, and this requires the use of sophisticated solvent pumping mechanisms along with extra steps and precautions in the chromatographic analysis. Enlightened by the prospect of using temperature gradient elutions for HPLC analyses, Hosoya et al. sought to make surface modification of HPLC stationary phases more accessible. Their study utilizes graft-type copolymerization of PNIPAAm onto macroporous polymeric materials. The in-situ preparation compared the use of cyclohexanol and toluene as porogens in the preparation of the modified polystyrene seeds. Reverse-phased size-exclusion chromatography (SEC) revealed pore size and pore size distribution of the particles and its dependence on temperature. Cyclohexanol acted as a successful porogen showing a dependent relationship of pore size to temperature. The use of toluene as a porogen gave results that were similar to unmodified macroporous particles. This indicates that PNIPAAm can be successfully grafted onto the surface and within the pores of macroporous materials. The application of this preparatory technique gives rise to tunable pore sizes. Temperature gradient elutions can be used to improve column efficiency through the changing of pore size in SEC.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.